Concordia Settles FTC Claims Over Drug Pact With Par

Concordia Healthcare Corp. and Par Pharmaceutical Holdings Inc. agreed to settle U.S. claims that the companies engaged in anticompetitive conduct by agreeing not to compete in the sale of a generic prescription drug.

Concordia and Par had an unlawful agreement in which Concordia agreed not to sell a generic version of Kapvay, which treats attention deficit hyperactivity disorder, likely raising prices for consumers, the Federal Trade Commission said Aug. 18.

“Concordia and Par reduced the number of competing generic Kapvay products available to consumers, depriving consumers of the lower prices that typically occur with generic competition,” Debbie Feinstein, the director ...